Evaluation of Alpha-Lipoic Acid in Diabetic Cardiomyopathy

Inclusion Criteria

• •Male or female adult age ≥ 18 years
• •patient with diagnosed type 2 diabetes (history of pathological hyperglycemia according to WHO and HbA1c standards \>7% or ongoing treatment with oral antidiabetic agents).
• •Patients with stable cardiomyopathy (no hospitalization in cardiology in the month before inclusion) with a left ventricular ejection fraction (LVEF) \<50%.
• •patient who has signed an informed consent form
• •For women of childbearing age: effective contraception followed for at least 3 months before the start of the study and agreeing to keep it for the duration of the study.
• •affiliation to a social security scheme.
• •with an implanted vascular stent less than 6 weeks before the examination;
• •carrier of an implanted biomedical device deemed "not safe" or "unsafe" in the list: http://www.mrisafety.com/TheList\_search.asp;
• •Beneficiary of an acquisition procedure that does not respect the conditions required by "conditional" use in a subject carrying an implanted biomedical material considered "conditional" in the list: http://www.mrisafety.com/TheList\_search.asp;
• •carrier of a ferromagnetic intraocular or intracranial foreign body close to the nerve structures;
• •carrying biomedical equipment such as a cardiac, neural or sensory pacemaker (cochlear implant) or a ventricular bypass valve without medical and paramedical supervision trained to perform MRI in these subjects;